Myovant Sciences Ltd

Myovant Sciences — Technical Presentation (May 2019)

21 slides from Myovant Sciences's technical presentation, May 14, 2019

  1. Slide 1: LIBERTY 1 Phase 3 Uterine Fibroid Study Results

    LIBERTY 1 Phase 3 UTERINE FIBROID study results May 14, 2019 Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical statements of fact and statements regarding the Company’s intent, bel

  3. Slide 3: LIBERTY 1 Phase 3 Uterine Fibroid Study Results

    LIBERTY 1 Phase 3 UTERINE FIBROID study results May 14, 2019

  4. Slide 4: LIBERTY 1: Positive Efficacy & Safety Results

    LIBERTY 1: Positive Efficacy & Safety Results Primary endpoint achieved (p < 0.0001) Relugolix combination therapy: 73.4% Placebo: 18.9% Six key secondary endpoints achieved with statistical significance Bone density comparable to placebo Generally well tolerated with adverse event rates comparable

  5. Slide 5: LIBERTY 1: Phase 3 Study Design

    LIBERTY 1: Phase 3 STUDY design PRIMARY ENDPOINT Proportion of women with < 80 mL menstrual blood loss/cycle and ≥ 50% reduction in menstrual blood loss by alkaline hematin method Relugolix Combination Therapy (N = 128) Uterine Fibroids and Heavy Menstrual Bleeding N = 388 Double-Blind Treatment: 24

  6. Slide 6: Baseline Characteristics and Demographics Were Well-Balanced across Groups

    Baseline characteristics and demographics were Well-Balanced across Groups LIBERTY 1 Demographics and Baseline Characteristics Relugolix Combination Therapy (N = 128) Relugolix à Relugolix Combination Therapy (N = 132) Placebo (N = 127) Age (mean, SD in years) 42.5 (5.0) 41.3 (5.4) 42.2 (5.4) Geogra

  7. Slide 7: LIBERTY 1 Achieved Primary Endpoint Responder Analysis

    LIBERTY 1 achieved primary endpoint responder analysis Proportion of Women (%) PRIMARY ENDPOINT COMPONENTS OF PRIMARY ENDPOINT Proportion of Women (%) < 80 mL Menstrual Blood Loss per Cycle Reduction ≥ 50% from Baseline Error bars denote 95% confidence interval Relugolix combination therapy = relugo

  8. Slide 8: 84.3% Average Reduction in Menstrual Blood Loss at Week 24

    Error bars denote 95% confidence interval Relugolix combination therapy = relugolix 40 mg + estradiol 1.0 mg and norethindrone acetate 0.5 mg Mean Change in Menstrual Blood Loss (%) P < 0.0001 ON AVERAGE, 84.3% REDUCTION IN MENSTRUAL BLOOD LOSS AT WEEK 24 Significant improvement in symptom most rele

  9. Slide 9: Six Key Secondary Endpoints Achieved by Relugolix Combination Therapy

    Six KEY Secondary Endpoints Achieved BY RELUGOLIX COMBINATION Key Secondary Endpoints p-value REDUCTION IN MENSTRUAL BLOOD LOSS Percent mean change in menstrual blood loss from baseline to Week 24 p < 0.0001 amenorrhea Proportion of women who achieve amenorrhea p < 0.0001 REDUCTION IN PAIN Proportio

  10. Slide 10: Change in Bone Density Comparable to Placebo

    CHANGE IN BONE DENSITY comparable to PLACEBO Mean % Change from Baseline to Week 24 in Bone Mineral Density (Lumbar Spine) Mean Change from Baseline (%) Error bars denote 95% confidence interval Relugolix combination therapy = relugolix 40 mg + estradiol 1.0 mg and norethindrone acetate 0.5 mg Place

  11. Slide 11: Distribution of Change in Bone Mineral Density Comparable to Placebo

    Distribution of change in bone density comparable to placebo distribution of change in bone MINERAL density at week 24 (lumbar spine) Relugolix combination therapy = relugolix 40 mg + estradiol 1.0 mg and norethindrone acetate 0.5 mg Placebo Relugolix Combination Therapy Percent Change from Baseline

  12. Slide 12: Combination Approach Maintained Bone Density Through Weeks

    combination approach maintained bone density through 24 weeks (lumbar spine) Error bars denote 95% confidence interval Relugolix combination therapy = relugolix 40 mg + estradiol 1.0 mg and norethindrone acetate 0.5 mg Mean Change from Baseline (%) Relugolix à Relugolix Combination Therapy Relugolix

  13. Slide 13: Summary of Adverse Events

    Summary of adverse events Number (%) of Women Relugolix Combination Therapy (N = 128) Relugolix à Relugolix Combination Therapy (N = 132) Placebo (N = 127) At least one adverse event 79 (62%) 96 (73%) 84 (66%) Adverse event leading to study discontinuation 7 (5%) 16 (12%) 5 (4%) Serious adverse even

  14. Slide 14: Relugolix Combination: LIBERTY Key Takeaways and Next Steps

    Relugolix combination: LIBERTY 1 key takeaways and Next steps Phase 3 LIBERTY 2 study results expected in Q3 2019 NDA filing planned for Q4 2019; on track to launch with single pill, once daily regimen for relugolix combination Data to be submitted for presentation and publication in 2019 Bone miner

  15. Slide 15: Uterine Fibroids Is a Debilitating Disease

    Uterine Fibroids is a debilitating Disease Baird, Am J Obstet Gynecol, 2003, Buletti J Assist Reprod Genet. 2010; Bulun New Engl J Med, 2013; Cohen, Obstet Gynec. 2017; Wright, Obstet Gynec. 2013; Barrett, Agency for Healthcare Research and Quality, 2016; Stewart, NEJM. 2015; Stewart J Women’s Healt

  16. Slide 16: Great Need in Uterine Fibroids and Endometriosis

    Endometriosis Foundation, American College of OB/Gyn; Bulletti et al. J Assist Reprod Genet. 2010; Quaas et al. Fertil Steril. 2015; Stewart. NEJM. 2015; Stewart. Lancet. 2001; Majoribanks et al. Cochrane Database Syst. Rev. 2006. Great need in uterine fibroids and endometriosis ~11M ~4M A MULTI-BIL

  17. Slide 17: What Do Women and OBGYNs Want?

    Proprietary quantitative market research survey conducted in February 2019; Sample size of 160 OBGYNs, 140 UF patients what do Women and obgyns want? WOMEN “The ideal treatment would be non-invasive” “Patients often don’t want surgery and available medical options aren’t great” Non-Surgical Option “

  18. Slide 18: Vision for Relugolix Combination Therapy

    Vision for relugolix combination therapy ONE PILL ONCE A DAY DESIGNED FOR WOMEN Provide predictable efficacy: bleeding, pain, anemia, quality of life Maintain bone health and mitigate hot flashes Enable long-term use Improve patient adherence and therapeutic effect Minimize spotting and breakthrough

  19. Slide 19: Recent Studies Investigating Oral GnRH Antagonists for Uterine Fibroids

    Recent studies investigating Oral GnRH Antagonists for Uterine Fibroids LIBERTY 1 ELARIS UF-1 ELARIS UF-2 Dosing Once Daily Twice Daily Same dose for Endometriosis Different doses for Endometriosis Responder Rate: Heavy Menstrual Bleeding 73.4% 68.5% 76.2% Bone Mineral Density Loss at 24 Weeks (Lumb

  20. Slide 20: Myovant's Late-Stage Pipeline

    Myovant’s Late-Stage Pipeline INDICATION PHASE 1 PHASE 2 PHASE 3 2019 – Q1 2020 RELUGOLIX COMBINATION THERAPY Uterine Fibroids Heavy Menstrual Bleeding Phase 3 Data (Q2/Q3 2019) NDA Filling (Q4 2019) Endometriosis Pain Phase 3 Data (Q1 2020) RELUGOLIX Advanced Prostate Cancer Phase 3 Data (Q4 2019)

  21. Slide 21: Myovant Sciences

    Of MYOVANT SCIENCES LIBERTY T

Myovant Sciences — Technical Presentation (May 2019) on 6ix